Article Details

Pfizer secures rights for RSV therapeutic candidate sisunatovir in China

Retrieved on: 2022-12-20 11:10:28

Tags for this article:

Click the tags to see associated articles and topics

Pfizer secures rights for RSV therapeutic candidate sisunatovir in China. View article details on HISWAI: https://www.pharmaceutical-technology.com/news/pfizer-rsv-therapeutic-sisunatovir/

Excerpt

LianBio has announced that Pfizer opted in to secure the right to develop and commercialise the RSV therapeutic candidate, sisunatovir.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up